References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailAdditive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis
Johnell, O.; Scheele, W. H.; Lu, Y. L. et al

in Journal of Clinical Endocrinology and Metabolism (2002), 87(3), 985-992

Both raloxifene (RLX) and alendronate (ALN) can treat and prevent new vertebral fractures, increase bone mineral density (BMD), and decrease biochemical markers of bone turnover in postmenopausal women ... [more ▼]

Both raloxifene (RLX) and alendronate (ALN) can treat and prevent new vertebral fractures, increase bone mineral density (BMD), and decrease biochemical markers of bone turnover in postmenopausal women with osteoporosis. This phase 3, randomized, double-blind 1-yr study assessed the effects of combined RLX and ALN in 331 postmenopausal women with osteoporosis (femoral neck BMD T-score, less than -2). Women (aged less than or equal to75 yr; greater than or equal to2 yr since their last menstrual period) received placebo, RLX 60 mg/d, ALN 10 mg/d, or RLX 60 mg/d and ALN 10 mg/d combined. At baseline, 6 and 12 months, BMD was measured by dual x-ray absorptiometry. The bone turnover markers serum osteocalcin, bone-specific alkaline phosphatase, and urinary N- and C-telopeptide corrected for creatinine were measured. The effects of RLX and ALN were considered to be independent and additive if the interaction effect was not statistically significant (P > 0.10) in a two-way ANOVA model. All changes in BMD and bone markers at 12 months were different between placebo and each of the active treatment groups, and between the RLX and RLX+ALN groups (P < 0.05). On average, lumbar spine BMD increased by 2.1,4.3, and 5.3% from baseline with RLX, ALN, and RLX+ALN, respectively. The increase in femoral neck BMD in the RLX+ALN group (3.7%) was greater than the 2.7 and 1.7% increases in the ALN (P = 0.02) and RLX (P < 0.001) groups, respectively. The changes from baseline to 12 months in bone markers ranged from 7.1 to -16.0% with placebo, -23.8 to -46.5% with RLX, -42.3 to -74.2% with ALN, and -54.1 to -81.0% in the RLX+ALN group. RLX and ALN increased lumbar spine and femoral neck BMD, and decreased osteocalcin and C-telopeptide corrected for creatinine in an additive and independent manner, because the interaction effects were not significant. Although the ALN group had changes in BMD and bone markers that were approximately twice the magnitude as in the RLX group, it is not known how well these changes correlate to the clinical outcome of fracture. RLX+ALN reduced bone turnover more than either drug alone, resulting in greater BMD increment, but whether this difference reflects better fracture risk reduction was not assessed in this study. [less ▲]

Detailed reference viewed: 49 (3 ULiège)
Full Text
Peer Reviewed
See detailAdministration of a supplement containing both calcium and vitamin D is more effective than calcium alone to reduce secondary hyperparathyroidism in postmenopausal women with low 25(OH)vitamin D circulating levels
Deroisy, Rita ULiege; Collette, Julien ULiege; Albert, Adelin ULiege et al

in Aging Clinical & Experimental Research (2002), 14(1), 13-17

Background and aims: Supplementation of postmenopausal women with calcium alone or calcium-vitamin D association was suggested to have positive effects on bone turnover and bone density, as well as to ... [more ▼]

Background and aims: Supplementation of postmenopausal women with calcium alone or calcium-vitamin D association was suggested to have positive effects on bone turnover and bone density, as well as to lower fracture incidence. The beneficial effect appears to be mediated by a reduction in parathyroid hormone secretion. Our aim was to compare the respective efficacy of calcium and calcium-vitamin D supplements in reducing serum parathyroid hormone levels in postmenopausal women with prevalent low 25(OH)vitamin D levels. Methods: One hundred consecutive ambulatory postmenopausal women with serum 25(OH)vitamin D levels below 18 ng/mL were included in a randomized, prospective, open label study. For a duration of 90 days, the women were randomly assigned to a daily supplementation of either one tablet of calcium gluconolactate and carbonate (500 mg calcium), or one powder-pack of an association of calcium carbonate (500 mg calcium), citric acid (2.175 gr) and cholecalciferol (200 IU). Changes observed during the 90 days of the study in circulating PTH levels were the primary endpoint, while changes in serum 25(OH)D levels were assessed as secondary endpoint. Results: A significant difference was observed between the calcium-vitamin D (CaD) and the calcium (Ca) only groups for changes occurring during the 90 days of the study in PTH (-14.5 +/- 40% and +2.5 +/- 46%) (p=0.009) and 25(OH)D (+67 +/- 77% and +18 +/- 55%) (p<0.001) circulating levels. PTH changes between baseline and day 90 were significant in the CaD group, but not in the Ca group. The odds ratio for a patient in group Ca to experience an absolute (<12 ng/mL) deficiency in circulating 25(OH)vitamin D levels, compared to a group CaD patient was statistically increased (OR: 3.22, 95% CI: 1.33-7.80). Conclusions: Our results support the recommendation of supplementing postmenopausal women with low circulating levels of 25(OH)vitamin D with a combination of calcium and vitamin D, rather than with calcium alone. [less ▲]

Detailed reference viewed: 32 (4 ULiège)
Full Text
Peer Reviewed
See detailInfluence of daily regimen calcium and vitamin D supplementation on parathyroid hormone secretion
Reginster, Jean-Yves ULiege; Zegels, Brigitte ULiege; Lejeune, Emmanuelle ULiege et al

in Calcified Tissue International (2002), 70(2), 78-82

Calcium and vitamin D supplementation has been shown to reduce secondary hyperparathyroidism and play a role in the management of senile osteoporosis. In order to define the optimal regimen of calcium and ... [more ▼]

Calcium and vitamin D supplementation has been shown to reduce secondary hyperparathyroidism and play a role in the management of senile osteoporosis. In order to define the optimal regimen of calcium and vitamin D supplementation to produce the maximal inhibition of parathyroid hormone secretion, we have compared the administration of a similar amount of Ca and vitamin D, either as a single morning dose or split in two doses, taken 6 hours apart. Twelve healthy volunteers were assigned to three investigational procedures, at weekly intervals. After a blank control procedure, when they were not exposed to any drug intake, they received two calcium-vitamin D supplement regimens including either two doses of Orocal D3 (500 mg Ca and 400 IU vitamin D) 6 hours apart or one water-soluble effervescent powder pack of Cacit D3 in a single morning dose (1000 mg Ca and 880 IU vitamin D). During the three procedures (control and the two calcium-vitamin D supplementations), venous blood was drawn every 60 minutes for up to 9 hours, for serum Ca and serum PTH measurements. The order of administration of the two Ca and vitamin D supplementation sequences was allocated by randomization. No significant changes in serum Ca were observed during the study. During the 6 hours following Ca and vitamin D supplementation, a statistically significant decrease in serum PTH was observed with both regimens, compared with baseline and with the control procedure. Over this period of time, no differences were observed between the two treatment regimens. However, between the sixth and the ninth hour, serum PTH levels were still significantly decreased compared with baseline with split dose Orocal D3 administration, while they returned to baseline value with the Cacit D3 preparation. During this period, the percentage decrease in serum PTH compared with baseline was significantly more pronounced with Orocal D3 than with Cacit D3 (P = 0.0021). We therefore conclude that the administration of two doses of 500 mg of calcium and 400 IU of vitamin D3 6 hours apart provides a more prolonged decrease in serum PTH levels than the administration of the same total amount of Ca and vitamin D as a single morning dose in young healthy volunteers. This might have implications in terms of protection of the skeleton against secondary hyperparathyroidism and increased bone resorption and turnover in elderly subjects. [less ▲]

Detailed reference viewed: 78 (13 ULiège)
Full Text
Peer Reviewed
See detailThe inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives
Henrotin, Yves ULiege; Sanchez, Christelle ULiege; Reginster, Jean-Yves ULiege

in Expert Opinion on Therapeutic Patents (2002), 12(1), 29-43

The objective of this paper is to analyse the potential therapeutic action of MMP inhibitors in the management of osteoarthritis (OA), based on a critical review of the literature. The role played by ... [more ▼]

The objective of this paper is to analyse the potential therapeutic action of MMP inhibitors in the management of osteoarthritis (OA), based on a critical review of the literature. The role played by metalloproteinases (MPs) in the pathophysiology of osteoarthritis is discussed, as well as their regulation by tissular inhibitors, activators and cytokines. The evidences that commonly used drugs for treating osteoarthritis are also active on MPs synthesis is also reported. Finally, this paper provides an analysis of the recent patents published with promising therapeutic potential and gives new perspectives for anti-MPs therapy. [less ▲]

Detailed reference viewed: 31 (6 ULiège)
Full Text
See detailBiochemical markers in glucocorticoid-induced osteoporosis
Bruyère, Olivier ULiege; Stephaniak, N; Reginster, Jean-Yves ULiege

in Giustina, A.; Angeli, A.; Canalis, E. (Eds.) et al Glucocorticoid-induced osteoporosis (2002)

Detailed reference viewed: 42 (16 ULiège)
Full Text
Peer Reviewed
See detailFracture prevention in postmenopausal women.
Bruyère, Olivier ULiege; Edwards, John; Reginster, Jean-Yves ULiege

in Clinical Evidence (2002), 8

Detailed reference viewed: 37 (24 ULiège)
Full Text
Peer Reviewed
See detailRecommendations for the design of clinical trials and the registration of drugs used in the treatment of asthma
Holgate, ST; Bousquet, J; Chung, KF et al

in International Journal of Pharmaceutical Medicine (2002), 16

Detailed reference viewed: 13 (1 ULiège)
Peer Reviewed
See detailL'audit en médecine générale : outils de dépistage et d'intervention
Filée, Dominique ULiege; Gosset, Christiane ULiege; Dor, B et al

Conference (2002)

Detailed reference viewed: 21 (3 ULiège)
Full Text
Peer Reviewed
See detailModels for assessing the cost-effectiveness of the treatment and prevention of osteoporosis
Zethraeus, N.; Ben Sedrine, Wafa ULiege; Caulin, F. et al

in Osteoporosis International (2002), 13(11), 841-857

Detailed reference viewed: 82 (15 ULiège)
Full Text
Peer Reviewed
See detailOsteoporosis in the very elderly
Halkin, V; Bruyère, Olivier ULiege; Reginster, Jean-Yves ULiege

in Medicographia (2002), 24(4), 316-321

Detailed reference viewed: 14 (4 ULiège)
Full Text
Peer Reviewed
See detailStrontium ranelate in osteoporosis
Reginster, Jean-Yves ULiege

in Current Pharmaceutical Design (2002), 8

Detailed reference viewed: 13 (3 ULiège)
Full Text
Peer Reviewed
See detailNew perspectives n the medical management of osteoarthritis
Reginster, Jean-Yves ULiege

in Osteoarthritis and Cartilage (2002), 10(SA), 18-19

Detailed reference viewed: 6 (1 ULiège)
Full Text
Peer Reviewed
See detailPain relief is not a confounder in joint space narrowing assessment of full extension knee radiographs
Pavelka, K.; Rovati, L. C.; Gatterova, J. et al

in Osteoarthritis and Cartilage (2002), 10(SA), 16-17

Detailed reference viewed: 15 (5 ULiège)
Full Text
Peer Reviewed
See detailRelevance of bone mineral density, bone quality and falls in reduction of vertebral and non-vertebral fractures
Reginster, Jean-Yves ULiege

in Osteoporosis International (2002), 13(S1), 157

Detailed reference viewed: 4 (1 ULiège)
Full Text
Peer Reviewed
See detailDose-related bone effects of strontium ranelate in postmenopausal women
Meunier, P. J.; Reginster, Jean-Yves ULiege

in Osteoporosis International (2002), 13(S1), 153

Detailed reference viewed: 8 (2 ULiège)
Full Text
Peer Reviewed
See detailStrontium ranelate antifracture study program : current data
Reginster, Jean-Yves ULiege; Meunier, P. J.

in Osteoporosis International (2002), 13(S1), 153-154

Detailed reference viewed: 3 (1 ULiège)
Full Text
Peer Reviewed
See detailThe effect of health related quality of life on reported use of health care resources in patients with osteoarthritis and rheumatoid arthritis: a longitudinal analysis.
Ethgen, Olivier ULiege; Kahler, Kristijan H; Kong, Sheldon X et al

in Journal of Rheumatology (2002), 29(6), 1147-55

OBJECTIVE: In today's cost conscious environment, health services researchers are consistently trying to find ways to predict future health care resource utilization (HCRU) and its associated costs. We ... [more ▼]

OBJECTIVE: In today's cost conscious environment, health services researchers are consistently trying to find ways to predict future health care resource utilization (HCRU) and its associated costs. We evaluated the impact of health related quality of life (HRQL) on future HCRU in patients with arthritis. METHODS: A total of 642 patients with rheumatoid arthritis (RA) and 395 patients with osteoarthritis (OA) completed at least 2 and as many as 6 consecutive surveys at 6 mo intervals. Information collected included demographics, HRQL questionnaires [Medical Outcome Study Short Form 36 (SF-36), Western Ontario McMaster Universities Osteoarthritis Index (WOMAC), and the Stanford Health Assessment Questionnaire (HAQ)], and HCRU over the previous 6 months. Longitudinal data analysis was perfomed to assess the effect of HRQL on future HCRU. RESULTS: Statistically significant associations between HCRU and HRQL variables were noted. Higher rates of HCRU were found in those in the worst quarter compared with those in the best quarter of HRQL. With the HAQ, OA and RA patients in the worst quarter reported a 199% (p < 0.05) and 48% (p < 0.05) increase in rheumatologist visits, respectively. With the WOMAC Function, increases were as high as 196% (p < 0.05) in rheumatologist visits for patients with OA. Patients with RA with a high level of HRQL as measured by the SF-36 (physical component score) reported a decrease of 31% (p < 0.01) in general practitioner visits and a decrease of 52% (p < 0.01) in hospitalization (mental component score). CONCLUSION: These findings suggest that HRQL may be used to predict future health care consumption. Such an approach may lead to a more efficient allocation of resources by providing useful information to health care providers and health care decision makers. [less ▲]

Detailed reference viewed: 20 (3 ULiège)
Full Text
Peer Reviewed
See detailCharacterization of the Metabolism of Osteoarthritic Chondrocytes Cultured in Alginate Beads
Sanchez, Christelle ULiege; Mathy, Marianne ULiege; Deberg, Michelle ULiege et al

in Osteoarthritis and Cartilage (2002), 10(SA), 34

Detailed reference viewed: 22 (11 ULiège)
Full Text
Peer Reviewed
See detailStructure-modifying drugs in osteoarthritis
Reginster, Jean-Yves ULiege; Kvasz, Angela ULiege

in Osteoporosis International (2002), 13(Suppl. 1), 49-50

Detailed reference viewed: 26 (16 ULiège)